Nektar Therapeutics (NKTR) EPS (Weighted Average and Diluted) (2013 - 2026)
Nektar Therapeutics (NKTR) recorded quarterly EPS (Weighted Average and Diluted) of -$1.82 in Q1 2026, down 14.47% quarter-over-quarter from -$1.59 in Q4 2025, and up 49.72% on a YoY basis from -$1.22 in Q1 2025.
Nektar Therapeutics (NKTR) EPS (Weighted Average and Diluted) (2013 - 2026) Analysis & Trends
Nektar Therapeutics' EPS (Weighted Average and Diluted) history runs 14 years deep, the most recent figure standing at -$1.82 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 49.72% year-over-year to -$1.82; the TTM figure through Mar 2026 stood at -$8.23 (up 12.91% YoY), while the FY2025 annual figure was -$9.73, down 12.1% from the prior year.
- EPS (Weighted Average and Diluted) was -$1.82 for Q1 2026 at Nektar Therapeutics, down from -$1.59 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.59 in Q4 2024 to a low of -$3.76 in Q2 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged -$1.25 across 5 years, with a median of -$0.73 in 2023.
- The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) jumped 368.18% in 2024, then tumbled 1805.26% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.32 in 2022, then surged by 31.25% to -$0.22 in 2023, then surged by 368.18% to $0.59 in 2024, then sank by 369.49% to -$1.59 in 2025, then slipped by 14.47% to -$1.82 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$1.82 (Q1 2026), -$1.59 (Q4 2025), and -$1.87 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Nektar Therapeutics | 1.51 Bn | 939.55 Mn | 3.16 Mn | -1.82 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.82 |
| Dec 31, 2025 | -1.59 |
| Sep 30, 2025 | -1.87 |
| Jun 30, 2025 | -2.95 |
| Mar 31, 2025 | -3.62 |
| Dec 31, 2024 | 0.59 |
| Sep 30, 2024 | -2.66 |
| Jun 30, 2024 | -3.76 |
| Mar 31, 2024 | -0.19 |
| Dec 31, 2023 | -0.22 |
| Sep 30, 2023 | -0.24 |
| Jun 30, 2023 | -0.27 |
| Mar 31, 2023 | -0.73 |
| Dec 31, 2022 | -0.32 |
| Sep 30, 2022 | -0.31 |
| Jun 30, 2022 | -0.85 |
| Mar 31, 2022 | -0.49 |
| Dec 31, 2021 | -790.00 |
| Sep 30, 2021 | -0.70 |
| Jun 30, 2021 | -0.69 |